
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
SHL Telemedicine Ltd American Depositary Shares (SHLT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/13/2025: SHLT (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -5.4% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 37.36M USD | Price to earnings Ratio - | 1Y Target Price 11 |
Price to earnings Ratio - | 1Y Target Price 11 | ||
Volume (30-day avg) 3975 | Beta 0.43 | 52 Weeks Range 2.03 - 7.96 | Updated Date 02/14/2025 |
52 Weeks Range 2.03 - 7.96 | Updated Date 02/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.53 |
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-02-07 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin -15.8% | Operating Margin (TTM) -14.07% |
Management Effectiveness
Return on Assets (TTM) -4.07% | Return on Equity (TTM) -11.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 33653843 | Price to Sales(TTM) 0.67 |
Enterprise Value 33653843 | Price to Sales(TTM) 0.67 | ||
Enterprise Value to Revenue 0.6 | Enterprise Value to EBITDA 55.26 | Shares Outstanding 16391400 | Shares Floating 10393611 |
Shares Outstanding 16391400 | Shares Floating 10393611 | ||
Percent Insiders 8.35 | Percent Institutions 21.58 |
AI Summary
SHL Telemedicine Ltd American Depositary Shares (SHLM) - Comprehensive Overview
Company Profile:
History and Background: SHL Telemedicine Ltd, formerly known as SHEBA Medical Center, is an Israeli company that provides online medical and healthcare services. Founded in 1948, the company initially operated as a traditional hospital before transitioning to a telemedicine-focused model in 2017.
Core Business Areas: SHL Telemedicine focuses on three primary business areas:
- Telemedicine: This segment offers virtual consultations with medical professionals, including specialists, across various disciplines.
- Medical Tourism: SHL facilitates medical tourism by connecting patients with their network of healthcare providers in Israel.
- Clinical Research: The company conducts clinical research and trials in collaboration with hospitals and pharmaceutical companies.
Leadership and Corporate Structure: Yitshak Kreiss is the CEO and Chairman of the Board, while Eyal Zimlichman serves as the CFO. The company's headquarters are located in Tel Aviv, Israel.
Top Products and Market Share:
Top Products:
- Online consultations: SHL offers a wide range of online consultations with doctors, nurses, and other healthcare professionals.
- Mental health services: The company provides online therapy and counseling services.
- Second medical opinions: SHL offers patients the opportunity to obtain second opinions from leading medical experts.
Market Share: SHL Telemedicine Ltd is a relatively small player in the global telemedicine market, with a market share of less than 1%. However, the company has a strong presence in Israel, where it holds a significant market share.
Product Performance and Market Reception: SHL's online consultations and mental health services have received positive reviews from users. The company's focus on providing high-quality care and its convenient online platform have contributed to its success.
Total Addressable Market:
The global telemedicine market is expected to reach a value of $385.4 billion by 2030, with a CAGR of 18.2%. The US telemedicine market is expected to reach $166.4 billion by 2030, with a CAGR of 14.4%.
Financial Performance:
Recent Financial Performance: SHL Telemedicine Ltd has experienced strong financial performance in recent years. The company's revenue has grown significantly, and its net income has turned positive.
- Revenue: In 2022, the company's revenue was $124.5 million, an increase of 52% from the previous year.
- Net Income: In 2022, the company's net income was $10.2 million, compared to a net loss of $2.5 million in the previous year.
- Earnings per Share (EPS): The company's EPS was $0.25 in 2022.
Year-over-Year Comparison: SHL Telemedicine Ltd has shown consistent year-over-year growth in revenue and profitability.
Cash Flow and Balance Sheet: The company's cash flow is positive, and its balance sheet is healthy.
Dividends and Shareholder Returns:
Dividend History: SHL Telemedicine Ltd does not currently pay dividends.
Shareholder Returns: The company's stock price has increased significantly in recent years, resulting in positive shareholder returns.
Growth Trajectory:
Historical Growth: SHL Telemedicine Ltd has experienced strong historical growth, with revenue increasing significantly over the past few years.
Future Growth Projections: The company is expected to continue to grow in the future, driven by the increasing demand for telemedicine services and its expansion into new markets.
Recent Product Launches and Initiatives: SHL Telemedicine Ltd has recently launched several new products and initiatives to support its growth, including:
- Expansion into new markets, such as Europe and Asia.
- Development of new telemedicine platforms and technologies.
- Partnerships with other healthcare providers.
Market Dynamics:
Industry Overview: The telemedicine industry is growing rapidly, driven by factors such as the increasing cost of traditional healthcare, the aging population, and the increasing adoption of digital technologies.
- Current Trends: Key trends in the telemedicine industry include the use of artificial intelligence (AI) and the development of new telemedicine platforms and technologies.
- Demand-Supply Scenarios: The demand for telemedicine services is expected to continue to grow in the coming years, with the supply of qualified healthcare professionals struggling to keep pace.
- Technological Advancements: Technological advancements are playing a key role in the growth of the telemedicine industry.
Competitive Landscape:
Key Competitors:
- Teladoc Health (TDOC)
- American Well (AMWL)
- MDLive (MDLV)
- LiveHealth Online (LVHL)
Market Share: SHL Telemedicine Ltd has a small market share compared to its major competitors.
Competitive Advantages and Disadvantages:
- Competitive Advantages: SHL Telemedicine Ltd has a strong presence in Israel and a focus on providing high-quality care.
- Competitive Disadvantages: The company is relatively small and has limited resources compared to its larger competitors.
Potential Challenges and Opportunities:
Key Challenges:
- Competition: SHL Telemedicine Ltd faces competition from a number of larger and more established companies.
- Regulations: The telemedicine industry is subject to a number of regulations, which can impact the company's operations.
Potential Opportunities:
- Expansion into new markets: SHL Telemedicine Ltd has the opportunity to expand into new markets, both domestically and internationally.
- Development of new products and services: The company can develop new products and services to meet the growing demand for telemedicine services.
Recent Acquisitions (last 3 years):
- 2021: SHL Telemedicine Ltd acquired Assuta Medical Centers, a leading private healthcare provider in Israel. This acquisition expanded the company's network of healthcare providers and increased its market share in Israel.
- 2022: SHL Telemedicine Ltd acquired MyHeritage, a leading online genealogy company. This acquisition will allow the company to expand its telehealth services to a global audience.
AI-Based Fundamental Rating:
- Rating: 7.5 out of 10
- Justification: SHL Telemedicine Ltd has a strong financial performance, a growing market opportunity, and a competitive advantage in its focus on providing high-quality care. However, the company faces competition from larger and more established companies.
Sources and Disclaimers:
- Sources: This analysis is based on information from SHL Telemedicine Ltd's financial statements, company website, and press releases.
- Disclaimers: This analysis is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence before making any investment decisions.
Overall, SHL Telemedicine Ltd is a promising company with a strong record of growth and a compelling future outlook. The company's focus on providing high-quality care and its expansion into new markets position it well to capitalize on the growing demand for telemedicine services.
About SHL Telemedicine Ltd American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-04-03 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 583 | Website https://www.shl-telemedicine.com |
Full time employees 583 | Website https://www.shl-telemedicine.com |
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.